药明康德：业绩回顾：上调 2025 财年销售和资本支出指引，下半年利润率可能低于上半年-WuXi XDC (2268.HK)_ Earnings review_ Raised FY25 sales _ capex guidance, with 2H25 margin likely lower than 1H25

19 August 2025 | 10:43PM HKT WuXi XDC (2268.HK) Earnings review: Raised FY25 sales / capex guidance, with 2H25 margin likely lower than 1H25 | 2268.HK | | --- | | 12m Price Target: HK$55.70 | | Price: HK$58.10 | | Downside: 4.1% | In line with the profit alert, 1H25 revenue was Rmb2.7bn, +62% y/y and net profit Rmb746mn, +53% y/y, with NM improving to 27.6% from 26.4% in FY24 (particularly GM to 36.1% from 30.6%), as headwinds from new capacity ramp-up and partial maintenance were offset by improved operati ...